drugset / Trial / NCT03792958

Study of Challenge Meditech 082 (CM082) Tablets in Patients With Advanced Malignant Solid Tumors

NCT03792958

Phase 1 Unknown 19 enrolled AnewPharma Shanghai East Hospital · collab
NaSequentialOpen-labelTreatment

Summary

This is a Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Oral Dosing of CM082 tablets in Chinese Patients With Advanced Malignant Solid Tumors

Timeline

Start
2019-02-26
Primary completion
2023-06
Completion
2023-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CM082 Unknown 200 mg Oral
Subject CM082 Unknown 400 mg Oral
Subject CM082 Unknown 600 mg Oral
Subject CM082 Unknown 800 mg Oral

Indications